Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemoradiotherapy in Esophageal Cancer
NCT04177875Phase 2Unknown
- Sponsor
- Tongji Hospital
- Start
- May 2019
- Primary completion
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tongji Hospital. Status: unknown.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04177875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04177875.